MIAMI LAKES, Fla., July 28, 2014 (GLOBE NEWSWIRE) -- ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, is pleased to announce that it will be exhibiting its full range of products at the world's largest show for Clinical Chemistry – American Association for Clinical Chemistry (AACC) in Chicago, Illinois, U.S.A., from July 28-31, 2014.
Suresh Vazirani, Executive Chairman of the Board of Directors of ERBA Diagnostics, said, "We have been exhibiting at the AACC over the last several years with four key objectives: (i) showcase our existing products and new products expected to be launched in the short term; (ii) network with industry peers to explore partnerships with the goal of expanding our product portfolio; (iii) network with attending distributors from various countries with the goal of expanding our channel presence; and (iv) engage, and build relationships with, thought leaders in the health care profession in our efforts to continuously improve our products and services."
Mohan Gopalkrishnan, Chief Executive Officer of ERBA Diagnostics, added, "We are excited to showcase three new products – the Hb Vario for Hb A1c testing, the Laura urine analyser and the XL 400, for which we recently received clearance from the U.S. Food and Drug Administration (FDA) on the 510(k) premarket submission that ERBA Diagnostics had filed for the U.S. market."
ERBA is now strongly focused on new product developments and looks forward to the ever increasing product portfolio to serve the health care providers and patients worldwide.
About ERBA Diagnostics, Inc.
ERBA Diagnostics, Inc. (www.erbadiagnostics.com), headquartered in Miami Lakes, Florida, is a fully integrated in vitro diagnostics company that develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, clinical chemistry, hematology and diabetes through its six subsidiaries – Diamedix Corporation (U.S.), Delta Biologicals S.r.l. (Europe), ImmunoVision, Inc. (U.S.), Drew Scientific, Inc. (U.S.), JAS Diagnostics, Inc. (U.S.), and Erba Diagnostics Mexico S.A. (Latin America).
Safe Harbor Statement
Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect the business and prospects of ERBA Diagnostics, Inc., including, without limitation: ERBA Diagnostics may not be able to achieve its four key objectives, including, without limitation, the risks and uncertainties that ERBA Diagnostics' new products may not be commercially launched when anticipated, or at all, that ERBA Diagnostics may not enter into or otherwise achieve partnerships with industry peers and, if any such partnerships are entered into or achieved, then ERBA Diagnostics may not successfully expand its product portfolio, that ERBA Diagnostics may not successfully expand its channel presence, and that ERBA Diagnostics may not engage or build relationships with thought leaders and, if any such engagement or relationships are entered into or built, then ERBA Diagnostics may not successfully continuously improve its products and services; ERBA Diagnostics' ability to successfully market the three new products described above, and the anticipated timing thereof; the ability of such three new products to perform as expected; the ability of such three new products to complement and enhance ERBA Diagnostics' existing portfolio of instruments and reagent kits; the ability of such three new products to be a source of revenue growth and earnings growth for ERBA Diagnostics in the future or otherwise positively impact ERBA Diagnostics' financial condition, operating results and cash flows; ERBA Diagnostics may not be able to develop new products when anticipated, or at all; if ERBA Diagnostics develops any new products, then ERBA Diagnostics may not be able to receive the applicable or necessary regulatory approvals when anticipated, or at all; ERBA Diagnostics may not be able to successfully continuously increase its product portfolio; constantly changing, and ERBA Diagnostics' compliance with, governmental regulation; ERBA Diagnostics' ability to achieve cost advantages from its own manufacture of instrument systems, reagents and test kits; economic, competitive, political, governmental and other factors affecting ERBA Diagnostics and its operations, markets and products; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. In addition to the risks and uncertainties set forth above, investors should consider the economic, competitive, governmental, technological and other risks and uncertainties discussed in ERBA Diagnostics' filings with the Securities and Exchange Commission, including, without limitation, the risks and uncertainties discussed under the heading "Risk Factors" in such filings.